The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | NMS-153: NMS-01940153E in hepatocellular carcinoma
Lorenza Rimassa, MD, Humanitas University and IRCCS Humanitas Research Hospital Rozzano, Milan, Italy, discusses the ongoing Phase II NMS-153 trial (NCT05630937), which is studying patients with advanced hepatocellular carcinoma (HCC) previously treated with other systemic therapies. The drug NMS-01940153E has a novel mechanism of action and functions by blocking cellular replication. The aim of the NMS-153 trial is to confirm the findings of Phase I studies and test for efficacy, before moving onto combination therapy in different scenarios. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
